Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|MAP2K1 E203K PIK3CA amp||skin squamous cell carcinoma||predicted - sensitive||Metformin + Trametinib||Case Reports/Case Series||Actionable||In a clinical case study, a combination of Glucophage (metformin) and Mekinist (trametinib) resulted in a complete clinical response and continued remission for over two years in a patient with cutaneous squamous cell carcinoma with amplification of PIK3CA and harboring MAP2K1 E203K (PMID: 35005996).||35005996|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|